Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma

Journal of Clinical Oncology

Volumn 31, Issue 16, 2013, Pages 2024-2028

  Dickson, Mark A ^a   Tap, William D ^a   Keohan, Mary Louise ^a   D’Angelo, Sandra P ^a   Gounder, Mrinal M ^a   Antonescu, Cristina R ^a   Landa, Jonathan ^a   Qin, Li Xuan ^a   Rathbone, Dustin D ^a   Condy, Mercedes M ^a   Ustoyev, Yelena ^a   Crago, Aimee M ^a   Singer, Samuel ^a   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVANIB; CYCLIN DEPENDENT KINASE 4; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; FLAVOPIRIDOL; GEMCITABINE; IFOSFAMIDE; IMATINIB; IRINOTECAN; PALBOCICLIB; RETINOBLASTOMA PROTEIN; SUNITINIB; TRABECTEDIN; 6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 (5 PIPERAZIN 1 YLPYRIDIN 2 YLAMINO) 8H PYRIDO(2,3 D)PYRIMIDIN 7 ONE; 6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-(5-PIPERAZIN-1-YLPYRIDIN-2-YLAMINO)-8H-PYRIDO(2,3-D)PYRIMIDIN-7-ONE; ANTINEOPLASTIC AGENT; CDK4 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; TUMOR MARKER;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DEDIFFERENTIATED LIPOSARCOMA; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRY SKIN; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HEMATURIA; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MEDIAN SURVIVAL TIME; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIDE EFFECT; SYSTEMIC THERAPY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WELL DIFFERENTIATED LIPOSARCOMA; CELL DIFFERENTIATION; CHEMISTRY; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; KAPLAN MEIER METHOD; LIPOSARCOMA; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CYCLIN-DEPENDENT KINASE 4; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LIPOSARCOMA; MALE; MIDDLE AGED; PIPERAZINES; PYRIDINES; RETINOBLASTOMA PROTEIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84880695940     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.5476     Document Type: Article

References (17)

1. Conyers R, Young S, Thomas DM: Liposarcoma: Molecular genetics and therapeutics. Sarcoma [epub ahead of print on December 27, 2010]
2. Dalal KM, Kattan MW, Antonescu CR, et al: Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg 244:381-391, 2006
3. Crago AM, Singer S: Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol 23:373-378, 2011
4. Binh MB, Sastre-Garau X, Guillou L, et al: MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: A comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 29:1340-1347, 2005
5. Sirvent N, Coindre JM, Maire G, et al: Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: Utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol 31:1476-1489, 2007
6. Tap WD, Eilber FC, Ginther C, et al: Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization. Genes Chromosomes Cancer 50:95-112, 2011
7. Singer S, Socci ND, Ambrosini G, et al: Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 67:6626-6636, 2007
8. Barretina J, Taylor BS, Banerji S, et al: Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 42:715-721, 2010
9. Fry DW, Harvey PJ, Keller PR, et al: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427-1438, 2004
10. Toogood PL, Harvey PJ, Repine JT, et al: Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 48:2388-2406, 2005
11. Schwartz GK, LoRusso PM, Dickson MA, et al: Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 104:1862-1868, 2011
12. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
13. Van Glabbeke M, Verweij J, Judson I, et al: Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38:543-549, 2002
14. Fleiss J: Statistical Methods for Rates and Proportions. New York, NY, Wiley, 1981, pp 13-15
15. Penel N, Van Glabbeke M, Marreaud S, et al: Testing new regimens in patients with advanced soft tissue sarcoma: Analysis of publications from the last 10 years. Ann Oncol 22:1266-1272, 2011
16. Luke JJ, D’Adamo DR, Dickson MA, et al: The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: Preclinical investigations and results of a phase I dose-escalation clinical trial. Clin Cancer Res 18:2638-2647, 2012
17. Louis-Brennetot C, Coindre JM, Ferreira C, et al: The CDKN2A/CDKN2B/CDK4/CCND1 pathway is pivotal in well-differentiated and dedifferentiated liposarcoma oncogenesis: An analysis of 104 tumors. Genes Chromosomes Cancer 50:896-907, 2011